Human Papillomavirus Genotype Replacement: Still Too Early to Tell?

ABSTRACT:

Background

Although human papillomavirus (HPV) vaccines are highly efficacious in protecting against HPV infections and related diseases, vaccination may trigger replacement by nontargeted genotypes if these compete with the vaccine-targeted types. HPV genotype replacement has been deemed unlikely, based on the lack of systematic increases in the prevalence of nonvaccine-type (NVT) infection in the first decade after vaccination, and on the presence of cross-protection for some NVTs.

Methods

To investigate whether type replacement can be inferred from early postvaccination surveillance, we constructed a transmission model in which a vaccine type and an NVT compete through infection-induced cross-immunity. We simulated scenarios of different levels of cross-immunity and vacci

SUBMITTER: Man I 

PROVIDER: S-EPMC8328199 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature